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http://dxBackground: Only local ablation (radiofrequency ablation, cryotherapy) or esophagectomy currently is avail-
able to treat high-grade dysplasia in Barrett’s esophagus. Alternative treatments, specifically chemopreventive
strategies, are lacking. Our understanding of the molecular changes of high-grade dysplasia in Barrett’s esoph-
agus offers an opportunity to inhibit neoplastic progression of high-grade dysplasia in Barrett’s esophagus. In-
creased activity of the Src kinase and deregulation of the tumor suppressor p27 are features of malignant cells
and high-grade dysplasia in Barrett’s esophagus. Src phosphorylates p27, inhibiting its regulatory function and
increasing cell growth and proliferation.We hypothesized that a small molecule inhibitor of Src might reduce the
growth and reverse Src-mediated deregulation of p27 in Barrett’s esophagus cells.
Methods: Immortalized Barrett’s esophagus cell lines established from patient biopsies were treated with the
Src kinase inhibitor dasatinib and evaluated for p27 localization and protein levels, as well as for effects on
the cell cycle and apoptosis using flow cytometry, viability assays, and protein and RNA markers.
Results: Dasatinib reduced both Src activation and p27 phosphorylation and increased p27 protein levels and
nuclear localization. These effects correlated with decreased proliferation, cell-cycle arrest, and activation of
apoptosis. Analysis of biopsies of patients with Barrett’s esophagus revealed the presence of phosphorylated
p27 in high-grade dysplasia, consistent with in vitro findings.
Conclusions: Dasatinib has considerable antineoplastic effects on Barrett’s esophagus cell lines carrying ge-
netic markers associated with dysplasia, which correlates with the reversal of p27 deregulation. These findings
suggest that dasatinib has potential as a treatment for patients with high-grade dysplasia and Barrett’s esophagus
and that p27 holds promise as a biomarker in the clinical use of dasatinib in patients with high-grade dysplasia
and Barrett’s esophagus. (J Thorac Cardiovasc Surg 2013;145:531-8)E
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SBarrett’s esophagus (BE) is the primary risk factor for
esophageal adenocarcinoma, one of the fastest growing
malignancies in the Western world.1,2 Progression
to early adenocarcinoma in nondysplastic BE is low
(0.5%-1% per year).1 However, this risk increases to
7.4% per year in BE with high-grade dysplasia (HGD),
with invasive cancer developing in 5 years in 50% of pa-
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The Journal of Thoracic and Cacurrent treatment paradigm for BE, specifically, annual or
biannual endoscopic surveillance for HGD and removal of
HGD lesions by endoscopic resection, radiofrequency/
cryoablation, or esophagectomy.5 The invasive nature of
these procedures has precipitated investigations into che-
mopreventive targets and agents as alternatives to noninva-
sively treat or control progression of HGD-BE.6,7
The Src family of kinases (cSrc, Lyn, Fyn, Yes, Lck, Blk,
Hck) is a group of protein tyrosine kinases that function in
the regulation of growth in eukaryotic cells.8 Activity of
Src kinases is regulated by a variety of stimuli, and in-
creased cSrc (or Src) kinase activity is a feature of several
solid tumor types,8 including esophageal adenocarcinoma.
Increased activity and expression of Src are also features of
HGD-BE.9-12 Src targets a diverse number of proteins
within the cell, one of which is the tumor suppressor p27.
Responsible for regulation of the cell cycle, p27 has been
found to be tyrosine phosphorylated by Src at 2 discrete
sites (tyrosine 74 and 88),13 leading to increased p27
proteolysis, reduced p27 inhibitory binding of cyclin
E-Cdk2, impaired p27 inhibition of cyclin D-cdk4 kinase
activity, and correlation with p27 cytoplasmic localizationrdiovascular Surgery c Volume 145, Number 2 531
Abbreviations and Acronyms
BE ¼ Barrett’s esophagus
DMSO ¼ dimethyl sulfoxide
HGD ¼ high-grade dysplasia
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Sin malignant tissues.13,14 The deregulation of p27 by Src
results in increased cell proliferation. Small molecule
inhibition of Src reverses these effects, restoring p27’s
ability to regulate the cell cycle and reduce growth.13 A
retrospective analysis of samples from patients with
HGD-BE has revealed increased p27 cytoplasmic localiza-
tion (48% of samples),12 suggesting involvement of p27
deregulation in the progression of BE. On the basis of
these previous observations in HGD-BE, we hypothesized
that Src inhibition may have value in controlling HGD-BE
and that Src alters the function of p27 in HGD-BE cells.
To test this hypothesis, we investigated the effects of
a small molecule inhibitor of the Src kinase (dasatinib)
on the growth and regulation of p27 in immortalized BE
cell lines.MATERIALS AND METHODS
Cell Lines and Patient Tissue
The human Barrett’s esophageal metaplastic (CP-A) and high-grade
dysplastic (CP-D) human cell lines were obtained from American Type
Culture Collection (Manassas, Va), maintained in recommended media
and grown and cultured as previously described.15 Both cell lines harbor
characteristic BE chromosomal abnormalities, increased ploidy, and
p16/CDKN2 inactivation, but differ in p53 status (CP-A-p53 wt; CP-D
p53 mutant). Although the CP-A cell line was established from a patient
with metaplasia, a recent report has suggested caution in interpreting these
cells as comparable to metaplasia because they have characteristics incon-
sistent with metaplastic BE.16 Patient tissues were obtained under a proto-
col approved by the institutional review board and managed by the Human
Specimen Procurement Service (St Joseph’s Hospital and Medical Center,
Phoenix, Ariz).
Drug Treatment
Dasatinib (Selleck Chemicals, Houston, Tex) was dissolved in dimethyl
sulfoxide (DMSO) to appropriateworking concentrations with final DMSO
less than 1%. All controls were treated with an equivalent volume of
DMSO diluted in culture media.
Biochemical Analysis
Total protein lysates from treated and untreated cells were isolated as
described previously.17 Sample protein, 25 to 40 mg, was separated on
12% sodium dodecyl sulfate polyacrylamide gel electrophoresis gels and
subsequently transferred to nitrocellulose at 4C overnight. Immunoblot-
ting was performed and developed as described previously.17 Antibodies
specific to p-p27-S10, p-p27-T198, and p-p27-T157 were obtained from
Abcam (Abcam, Cambridge, Mass). The p-p27-T187 antibody was ac-
quired from LifeSpan Biosciences (LifeSpan Biosciences, Inc, Seattle,
Wash). Antibodies to p27/Kip1, Src, phosphorylated Src (Y416),
cyclin D, cyclin E, and cleaved Parp were obtained from Cell Signaling
(Cell Signaling Technology, Boston, Mass).532 The Journal of Thoracic and Cardiovascular SurgQuantitative Reverse Transcriptase Polymerase
Chain Reaction
Total RNA isolated with the RNeasy Mini Kit (QIAGEN Inc, Valencia,
Calif) was used for first-strand cDNA synthesis using SuperScript III
(Invitrogen, Carlsbad, Calif) and oligo(dT) (Invitrogen). Custom designed
gene-specific primers (Invitrogen) were suspended to 10 mmol/L, com-
bined with LightCycler 480 SYBR Green I Master (Roche Applied Sci-
ence, Indianapolis, Ind) and 2 mL of the cDNA reaction. The samples
were analyzed in triplicate on the LightCycler 480 (Roche Applied Sci-
ence) and normalized to GAPDH. Fold change analysis was performed
as previously described.18
Cell Viability
A total of 250 cells per well were plated on a 96-well plate with 8 rep-
licates per treatment dose and allowed to attach overnight. Cells were
treated with the appropriate concentration of dasatinib diluted in cell cul-
ture media for 24 hours. Viability was assessed with the CellTiter-Glo
Luminescent Cell Viability Assay (Promega Corp, Madison, Wis) accord-
ing to the manufacturer’s instructions. Luminescence was read on the
DTX880 Multimode Detector (Beckman Coulter Inc, Indianapolis,
Ind). Viability of treated cells was determined relative to vehicle-
treated cells.
Immunofluorescence and Brightfield Imaging
2 3 105 cells were seeded onto glass coverslips and allowed to attach
overnight, followed by treatment with 100 nM dasatinib. Drug was
diluted from prepared stock and changed every 24 hours. Cells were fixed
with 4% paraformaldehyde, permeabilized with 0.1% saponin/
phosphate-buffered saline, and blocked with CAS Block (Invitrogen).
Primary (p27) and AlexaFluor488 conjugated secondary antibodies
were diluted in 0.5% bovine serum albumin/phosphate-buffered saline
and incubated overnight at 4C or 2 hours at room temperature, respec-
tively. Nuclei were stained and coverslips mounted onto glass
slides with Prolong Gold with DAPI (Invitrogen) according to the manu-
facturer’s instructions. Stained cells were visualized with a Zeiss 710 la-
ser scanning confocal microscope (Carl Zeiss Microscopy, LLC,
Thornwood, NY) equipped with a 633/1.4NA plan-apochromat objec-
tive. AlexaFluor488 (p27) was identified with 488 nm excitation and
505 to 525 nm emission. DAPI was identified with 405 nm excitation
and 410 to 460 nm emission. Emission spectra were collected separately
to minimize fluorophore overlap. Images were acquired with the confocal
aperture set to 1 Airy unit and managed in Zen 2009 v 5.5.0.375 software
(Carl Zeiss Microscopy, LLC). Brightfield images were viewed on a Zeiss
Axiovert 200M (Carl Zeiss Microscopy, LLC, Thornwood, NY) and cap-
tured with an AxioCam ERc5s camera (Carl Zeiss Microscopy, LLC)
at 103 magnification.
Flow Cytometry
To analyze the effects of dasatinib treatment on the cell cycle and ap-
optosis of BE cells, flow cytometry was performed on the Accuri C6 Flow
Cytometer (BD Biosciences, San Jose, Calif) with a threshold at 80,000
and 20,000 events collected per sample. Cells (1 3 106 cells/100-mm
dish) were allowed to attach overnight and treated with 100 nM dasatinib
for the indicated times. Assays were performed in triplicate and repeated.
Cell-cycle analysis was conducted using propidium iodide to stain DNA
content. RNA was eliminated with RNaseA. To determine apoptosis,
phosphatidylserine externalization was used as an apoptotic marker and
visualized using the Dead Cell Apoptosis Kit with Annexin V FITC
(Invitrogen) per the manufacturer’s recommended protocol. Phosphatidyl-
serine was visualized by Annexin V FITC conjugation indicative of
apoptosis. For comparison, cells were treated with camptothecin to induce
apoptotic death to establish proper gating. Compensations were set to
FL1-FL3 6%, FL3-FL1 5%.ery c February 2013
FIGURE 1. Dasatinib (DAS) treatment reduces p27 phosphorylation and induces relocalization of p27/Kip1 to the nucleus. A, Top: CP-D and CP-A cells
were treated for 4 hours with 100 nM dasatinib or vehicle (DMSO). Total protein lysates were probed for active (phosphorylated) Src (p-src Y416). Dasatinib
treatment results in reduced active Src. Bottom: CP-D and CP-A cells were probed with antibodies specific to phosphorylated-T187 p27 and p27. CP-D cells
display increased basal phsophoryated-T187 p27, compared with CP-A cells. b-Actin was used as a loading control. Blot is representative of 3 independent
experiments. B, Effect of dasatinib on p27 phosphorylation. CP-D and CP-A cells were treated with 100 nm (dasatinib) or vehicle (DMSO) for 24 hours.
Total protein lysates were probed using antibodies specific to phosphorylated T187-p27, T157-p27, S10-p27, or total p27. Dasatinib treatment results in
reduced p27 phosphorylation at all sites (S10, T157, T187) with a corresponding increase in total p27 levels. b-Actin was used as a loading control.
Blot is representative of 3 independent experiments. C, Immunofluorescence staining of p27 in CP-D and CP-A immortalized BE cell lines after
a 24-hour treatment with 100 nM dasatinib (dasatinib) or vehicle (DMSO) reveals relocalization of p27/kip1 (green) from the cytoplasm to the nucleus
(blue). V, Vehicle (dimethyl sulfoxide).
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SRESULTS
Dasatinib Reduces Src Activation in Immortalized
Barrett’s Esophagus Cells and Reverses p27
Deregulation
To investigate the effects of Src inhibition and p27 func-
tion in BE, we treated 2 immortalized BE cell lines estab-
lished from patient tissue, one diagnosed as without
dysplasia (CP-A) and one diagnosed with HGD (CP-D),15
with dasatinib, an inhibitor of Src kinase and Bcr-ABL on-
cogene, which is currently approved by the Food and Drug
Administration as a second-line treatment for chronic mye-
loid leukemia.8 CP-D and CP-A cells were treated with 100
nM dasatinib and analyzed by immunoblot for Src activa-
tion with an antibody specific to tyrosine 416, an indicator
of active Src. As shown in Figure 1, A, tyrosine phosphory-
lation at the 416 (p-Src Y416) site in both CP-D and CP-A
cells was reduced after a 4-hour exposure to dasatinib, with
the HGD CP-D cell line displaying increased active Src,The Journal of Thoracic and Carelative to the metaplastic CP-A cell line. On the basis of
the observed increased basal Src activity in CP-D and
CP-A cells, we performed an immunoblot analysis of p27
for phosphorylation at threonine 187 (T187), a site shown
to require Src tyrosine phosphorylation.13 Immunoblotting
with an antibody specific to p27 T187-phosphorylation
showed increased basal phosphorylation of p27 at the
T187 site in CP-D cells, compared with CP-A cells
(Figure 1, A, bottom). Treatment with dasatinib for 24 hours
reduced p27 T187 phosphorylation and increased total p27
protein levels (Figure 1, B), consistent with observations
that phosphorylation at T187 results in p27 proteosomal
degradation. p27 is phosphorylated at multiple sites in addi-
tion to T187 (serine 10-S10, threonine 157-T157, threonine
198-T198), which can contribute to p27 deregulation.19 We
immunoblotted dasatinib-treated BE protein lysates with
antibodies specific to phosphorylation at these sites (S10,
T157, T198) to ascertain whether Src inhibition had anyrdiovascular Surgery c Volume 145, Number 2 533
FIGURE 2. Dasatinib treatment results in cell-cycle arrest. A, Total RNA from vehicle-treated and dasatinib- (96 hours) treated CP-D and CP-A underwent
expression analysis of cyclins D and E. Fold change is relative to expression of cyclin D or E in vehicle-treated cells. Data represent the mean of 2 inde-
pendent experiments performed in duplicate. Bars represent standard error. B, Immunoblot analysis of cyclins D and E in CP-D and CP-A cells treated with
100 nM dasatinib for 24 or 96 hours. Asterisk indicates nonspecific band migrating below cyclin E. b-Actin was used as a loading control. Blot is repre-
sentative of 3 independent experiments. C, Cell-cycle analysis of CP-D cells after 96 hours of dasatinib (100 nM) treatment. CP-D cells were stained and
analyzed as described in ‘‘Materials andMethods.’’ Control represents cell-cycle profile of CP-D cells at the beginning of the experiment (0 hours). Data are
the mean of 2 independent experiments.
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Seffect on phosphorylation at those sites. Treatment with da-
satinib resulted in decreases in phosphorylation at both S10
and T157 (Figure 1, B), sites shown to be involved in sub-
cellular localization of p27.19 Consistent with these find-
ings, immunofluorescence of p27 showed that treatment
with 100 nM dasatinib induced the relocalization of p27
from the cytoplasm to the nucleus of both CP-D and
CP-A cells after 24 hours (Figure 1, C, compare vehicle
with 24 hours).TABLE 1. Dasatinib induces cell-cycle arrest at G1 in Barrett’s
esophagus cells
0 24 48 72 96
G1 37.60% 45.41% 64.48% 69.04% 73.27%
S 34.99% 26.3% 25.13% 24.94% 22.77%
G2 37.13% 33.67% 20.95% 14.52% 14.36%
CP-D cells were treated with dasatinib for 24, 48, 72, and 96 hours. Cell-cycle distri-
bution was determined using propidium iodide as described in ‘‘Materials and
Methods.’’ Results are the mean of 2 independent experiments.Dasatinib Induces Cell-Cycle Arrest in Barrett’s
Esophagus Cell Lines
Because treatment with dasatinib resulted in nuclear re-
localization and increased protein levels of p27 in BE cell
lines, we next investigated whether these changes correlated
with alterations in the cell cycle. p27 directly associates and
regulates cyclins D and E, 2 proteins necessary for progres-
sion through the cell cycle.13,14 Expression analysis of
CP-A and CP-D revealed that treatment with dasatinib re-
sulted in considerable decreases in the mRNA of both cy-
clins D and E in CP-D and CP-A cell lines and
particularly for cyclin D (Figure 2, A). To confirm these
findings, protein levels of cyclins D and E were assessed534 The Journal of Thoracic and Cardiovascular Surgin CP-D and CP-A BE cells treated with dasatinib for 24
and 96 hours. As shown in Figure 2, B, both cell lines dis-
played increases in protein levels of cyclins D and E after
24 hours of treatment. However, after 96 hours of dasatinib
treatment, both BE cell lines showed dramatic decreases in
cyclins D and E protein levels, consistent with the quantita-
tive polymerase chain reaction data at 96 hours (Figure 2,
C). We next analyzed the DNA content and cell-cycle pro-
file of CP-D cells treated with dasatinib by flow cytometry.
As shown in Table 1 and Figure 2, C, CP-D cells displayed
distinct changes in the percentages of cells in each cell-
cycle phase on treatment with dasatinib. Specifically, dasa-
tinib treatment resulted in a decrease in S (37.60% atery c February 2013
FIGURE 3. Dasatinib treatment results in activation of apoptosis in BE cells. A, CP-A and CP-Dwere treated with the indicated concentrations of dasatinib
for 24 hours. Viable cells were evaluated as described in ‘‘Materials and Methods.’’ Note that CP-D cells (derived from high-grade dysplasia) display sen-
sitivity to low nanomolar concentrations of dasatinib. Bars represent standard error. Data are the mean of 3 independent experiments. B, Brightfield images
of CP-D cells treated with 100 nM dasatinib for 72 hours. Note the increase in unattached, floating cells after 72 hours of treatment. C, Immunoblot analysis
of CP-A and CP-D cells for the apoptotic marker, cleaved Parp. CP-A and CP-D cells were treated as in (B), and total protein lysates were collected at the
indicated time points. b-Actin was used as a loading control. Blot is representative of 3 independent experiments. D, CP-D and CP-A cells were treated and
analyzed as described in ‘‘Materials and Methods.’’ Unfixed cells were collected at the indicated time points and evaluated for activation of apoptosis by
annexin V staining using flow cytometry.
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S0 hours vs 22.77% at 96 hours) and G2/M (37.13% at
0 hours vs 14.36% at 96 hours), phases with a corresponding
increase in G1 (37.6% at 0 hours vs 73.77% at 96 hours),
compared with vehicle-treated cells. Similar results were
observed in CP-A cells (data not shown).Prolonged Dasatinib Treatment Results in Apoptosis
in Barrett’s Esophagus Cell Lines
We next tested the response of CP-D and CP-A cells to
a range of dasatinib concentrations. After treatment for 24
hours, both CP-D and CP-A showed a significant decrease
in the number of viable cells to all concentrations of dasa-
tinib, compared with vehicle-treated cells (Figure 3, A).
CP-D cells, derived from HGD, responded to lower concen-
trations of dasatinib compared with CP-A cells. We ob-
served significant numbers of detached cells within the
media of treated cells (Figure 3, B), suggesting that cells
also could be activating apoptosis in response to dasatinib
treatment. To investigate this possibility, dasatinib-treated
CP-D and CP-A cells were analyzed by immunoblot using
an antibody specific to cleaved Parp, a marker of apoptosis.
Dasatinib treatment resulted in an increase in cleaved ParpThe Journal of Thoracic and Caat 48 hours, with maximal levels occurring after 96 hours of
treatment (Figure 3, C). To confirm these findings, we as-
sessed Annexin V staining, an early marker of apoptosis, af-
ter dasatinib treatment. Dasatinib treatment resulted in an
increase in Annexin V staining after 24 hours in both cell
lines, which remained throughout treatment (Figure 3, D).Phosphorylation of p27 in Barrett’s Esophagus
Patient Tissue
On the basis of the observations of increased p27 phos-
phorylation by Src in CP-A and CP-D cells, we subse-
quently investigated p27 phosphorylation in patient tissue
samples. Total protein lysates from patient biopsy samples
with pathologic diagnoses of metaplastic BE (n ¼ 4),
HGD-BE (n¼ 4), or esophagitis (n¼ 3) were immunoblot-
ted for p-T187 p27, p-T157 p27, p-S10 p27, total p27, and
Src kinase. As shown in Figure 4, levels of Src were in-
creased in patients with BE and HGD compared with pa-
tients with esophagitis, which is consistent with previous
observations.10,11 Phosphorylation of p27 at T187 was
present at increased levels in all BE tissues and 2 of 4
HGD tissues, compared with esophagitis (Figure 4, A),rdiovascular Surgery c Volume 145, Number 2 535
FIGURE 4. Abnormal phosphorylation of p27/Kip1 and increased expression of Src are present in biopsies of patients with Barrett’s esophagus (BE) and
high-grade dysplasia (HGD). A, Standard biopsies from patients diagnosed with metaplastic BE (n¼ 4), HGD (n¼ 4), or esophagitis (Es) (n¼ 3) were used
to isolate total protein as described in ‘‘Materials and Methods.’’ Lysates were separated using standard procedures and immunoblotted with antibodies
specific to p27 phosphorylated at T187 or S10. Lysates also were probed for total protein levels of Src and p27. b-Actin was used as a loading control.
B and C, Potential model for dasatinib in BE cells. B, p27 phosphorylation by Src reduces p27 inhibitory functions and results in cell-cycle progression
and p27 degradation. C, Inhibition of Src with small molecule inhibitors (eg, dasatinib) stabilizes p27 and allows p27 to inhibit function of cyclins E
and D and induce cell-cycle arrest.
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S whereas 3 of 4 HGD-BE samples showed increased S10
phosphorylation compared with BE and esophagitis
(Figure 4). Tissues of patients with HGD demonstrated in-
creased total levels of p27 compared with BE (Figure 4),
shown to be a consequence of p27 present throughout the
entire BE intestinal gland in HGD and restriction of p27
to superficial regions of the BE gland.12 Analysis of
p-T157 was inconclusive, with little to no staining in any
of the tissues (data not shown).
DISCUSSION
The present study explored the effects of a Food and Drug
Administration–approved, small molecule inhibitor of the
Src kinases, dasatinib, on BE cells. Treatment of immortal-
ized BE cell lines (metaplasia and HGD) in vitro with dasati-
nib results in reduced proliferation, cell-cycle arrest, and
apoptosis. These observations correlate with inhibition of
Src, p27 nuclear relocalization, increased protein levels of
p27, and reduction of p27 phosphorylation. These findings
collectively suggest that dasatinib and other Src kinase inhib-
itorsmayhave potential as chemopreventive agents forHGD-
BE and whose efficacy can be assessed by evaluation of p27.536 The Journal of Thoracic and Cardiovascular SurgPreclinical studies indicate that dasatinib and other Src
inhibitors have substantial chemotherapeutic activity in
malignant cells, inhibiting cell-cycle progression, prolifer-
ation, and metastasis, and activating apoptosis.8 The
current study found that dasatinib treatment results in
cell-cycle arrest after 96 hours of treatment (Figure 2, C,
and Table 1), increases cyclins D and E after 24 hours of
treatment, and decreases cyclin D and E expression at 96
hours (Figure 2, A and B) and apoptosis (Figure 3) in pre-
malignant BE cells. Further, these characteristics also are
found with p27-induced growth arrest20-22 and forced p27
expression in cells.23,24 These findings suggest that the
antineoplastic effects of dasatinib observed within BE
cell lines might be due to reversal of Src-mediated deregu-
lation of p27 and support a potential model for the effects of
dasatinib in our BE cell lines (Figure 4, B and C). Evidence
indicates that tyrosine phosphorylation of p27 by Src per-
mits T187-phosphorylation of p27 by cyclin E-cdk2, pro-
moting disassociation of p27 from the cyclin E-cdk2
complex and proteosomal degradation,13 as well as being
necessary for activation of the cyclin D-cdk4/6 complex14
(Figure 4, B). Combined, these events result in cell-cycleery c February 2013
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Sprogression. Inhibition of Src by dasatinib stabilizes p27
protein levels and nuclear relocalization, allowing p27 to
inhibit progression of the cell cycle and induce cell-cycle
arrest (Figure 4, C). However, because of the broad effects
of Src within eukaryotic cells,8 as well as dasatinib’s ability
to functionally inhibit other tyrosine kinases, it is possible
that dasatinib could be producing the observed responses
via inhibition of an Src-dependent or Src-independent path-
way. Our observations of reduction in other p27 phosphor-
ylation sites may reflect this possibility because
phosphorylation at these sites (S10, T157, T198) has
been linked to activity of other kinases.19 Thus, it will be
important in future investigations to definitively implicate
p27 as a mediator of dasatinib’s antineoplastic effects in
BE cells, a topic that is currently being pursued in our
laboratory.
Although dasatinib has displayed minimal efficacy in
late-stage solid tumors as amonotherapy,8 our evidence sug-
gests that dasatinib (even at low doses) could have benefits
for control of HGD-BE, a premalignant lesion. The current
state of treatment for HGD-BE focuses on local ablation or
surgical removal of the lesion.5 Although efficacious, these
procedures are expensive and often require multiple treat-
ments. In addition, the invasive nature of these procedures
can be unattractive to patients. Development of chemopre-
ventive strategies that limit and perhaps even eradicate the
HGD-BE lesion would have considerable patient benefit,
providing a safe, noninvasive method to control their BE.
Such an approach is not unfounded, as evidenced by the As-
pirin and Esomeprazole Chemoprevention (AspECT) in BE
trial currently ongoing in Europe and smaller studies inves-
tigating the chemopreventive potential of aspirin and other
nonsteroidal anti-inflammatory drugs.1,6 However, despite
the moderate efficacy of nonsteroidal anti-inflammatory
drugs in limiting BE progression,1,6 the cardiovascular,
gastrointestinal, and renal side effects of these agents have
limited their clinical application25 and led to the pursuit of
alternative modalities.
CONCLUSIONS
Our in vitro studies with dasatinib are an early prelim-
inary step toward an alterative chemopreventive agent for
HGD-BE. Our observations of reduced growth and apo-
ptosis at low doses of dasatinib could indicate that pa-
tients with HGD-BE may benefit from dasatinib at low
doses or short durations of treatment. Further, because
our studies show the occurrence of Src-dependent p27
phosphorylation and increased Src expression in HGD-
BE, evaluation of p27 localization or p27 phosphorylation
would be a useful marker for Src inhibition in both pre-
clinical and clinical studies. However, despite the benefi-
cial effects of dasatinib in BE cell lines, substantial
studies are necessary before dasatinib can be applied clin-
ically. Specifically, testing the efficacy of low-doseThe Journal of Thoracic and Cadasatinib in controlling BE progression, as well as devel-
oping dosing and treatment regimens in surgical rodent
models of BE, will be important before attempting patient
studies. Such studies are critical, because a chemopreven-
tive strategy for HGD-BE would beneficially affect early
adenocarcinoma by providing multiple avenues for early
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